^
No biomarker
|
Uterine Corpus Leiomyosarcoma
|
No biomarker
|
Uterine Corpus Leiomyosarcoma
|
pazopanib Sensitive: A2 - Guideline
|
pazopanib Sensitive: A2 - Guideline
|
ER positive
|
Uterine Corpus Leiomyosarcoma
|
ER positive
|
Uterine Corpus Leiomyosarcoma
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
medroxyprogesterone Sensitive: A2 - Guideline
|
medroxyprogesterone Sensitive: A2 - Guideline
|
ER positive
|
Uterine Corpus Leiomyosarcoma
|
ER positive
|
Uterine Corpus Leiomyosarcoma
|
medroxyprogesterone Sensitive: A2 - Guideline
|
medroxyprogesterone Sensitive: A2 - Guideline
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
megestrol Sensitive: A2 - Guideline
|
megestrol Sensitive: A2 - Guideline
|
ER positive
|
Uterine Corpus Leiomyosarcoma
|
ER positive
|
Uterine Corpus Leiomyosarcoma
|
megestrol Sensitive: A2 - Guideline
|
megestrol Sensitive: A2 - Guideline
|
AKT1 E17K
|
Uterine Corpus Leiomyosarcoma
|
AKT1 E17K
|
Uterine Corpus Leiomyosarcoma
|
AZD5363 Sensitive: C3 – Early Trials
|
AZD5363 Sensitive: C3 – Early Trials
|
CD70 expression
|
Uterine Corpus Leiomyosarcoma
|
CD70 expression
|
Uterine Corpus Leiomyosarcoma
|
ARX305 Sensitive: C3 – Early Trials
|
ARX305 Sensitive: C3 – Early Trials
|
ER positive + PGR positive
|
Uterine Corpus Leiomyosarcoma
|
ER positive + PGR positive
|
Uterine Corpus Leiomyosarcoma
|
anastrozole Sensitive: C3 – Early Trials
|
anastrozole Sensitive: C3 – Early Trials
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
anastrozole Sensitive: C3 – Early Trials
|
anastrozole Sensitive: C3 – Early Trials
|
ER positive
|
Uterine Corpus Leiomyosarcoma
|
ER positive
|
Uterine Corpus Leiomyosarcoma
|
anastrozole Sensitive: C3 – Early Trials
|
anastrozole Sensitive: C3 – Early Trials
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
lorlatinib Sensitive: C4 – Case Studies
|
lorlatinib Sensitive: C4 – Case Studies
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
alectinib Sensitive: C4 – Case Studies
|
alectinib Sensitive: C4 – Case Studies
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
crizotinib Resistant: C4 – Case Studies
|
crizotinib Resistant: C4 – Case Studies
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
|
pazopanib Resistant: C4 – Case Studies
|
pazopanib Resistant: C4 – Case Studies
|
